Label Image (Lbl500908003)
Estradiol / Norethindrone Acetate Tablet, Film Coated
Product Images NDC 50090-8003
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Estradiol / Norethindrone Acetate (NDC 50090-8003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Norethindrone 01)
Chemical Structure (Norethindrone 02)
Figure 1a (Norethindrone 03)
This text provides information on hormone levels in pg/mL, specifically Estradiol and Estrone. The values displayed are 500, 400+, 300, and 200. The data can be used for evaluating hormone levels in a medical or research context.*
Figure 1b (Norethindrone 04)
Figure 2 (Norethindrone 05)
This dataset appears to show the number of hot flushes per week for a study involving different treatments. The treatments include a placebo, 1mg Estradiol, and a combination of Estradiol+Norethindrone Acetate Tablets (1.0 mg/0.5 mg). The severity of hot flushes is likely being assessed based on the categories of "moderate" to "severe."*
Figure 3 (Norethindrone 06)
This text mentions the comparison between Estradiol Norethindrone Acetate tablets containing 0.5mg/0.1mg and Placebo in a study involving 198 and 199 participants respectively. Hints about a clinical trial or drug effectiveness evaluation can be inferred from the text.*
Figure 4 (Norethindrone 07)
This is a description of a medication known as "Estradiol/Norethindrone Acetate Tablets" with a strength of 1.0 mg/0.5 mg. The sample size mentioned is 290.*
Figure 5 (Norethindrone 08)
This text appears to show a comparison of different medications or treatments related to women's health, potentially involving the use of Estradiol/Norethindrone Acetate Tablets at different doses. The percentage values provided (100%, 80%, 70%, etc.) suggest a comparison or evaluation of the effectiveness or benefits of these treatments. The specific context and details of the comparison are not fully clear from the provided text.*
Figure 6 (Norethindrone 09)
This text mentions different forms of hormonal tablets containing Estradiol/Norethindrone in various doses, as well as a placebo. The study involved participants from the United States and the European Union, with different sample sizes (ranging from 31 to 40). The data is related to Lunar Month (28 day cycles), possibly indicating a study duration.*
Image (Norethindrone 10)
This is a set of instructions for using a Tablet Dispenser to take Estradiol/Norethindrone Acstate Tablets. The regimen starts in Row 1 of the dispenser, with tablets correlating to the day of the week. The user is advised to take tablets daily and at the end of the 28-day cycle. If tablets are left in Row 1 at the end of Row 4, they should be taken before starting a new cycle.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
